medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2017, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2017; 15 (2)

Toxic Epidermal Necrolysis Associated to Furosemide. A Case Report and Review

Gallardo RCE, Souza SMAG, Domínguez BA, Gutiérrez SCO, Cruz MRZ, Medina NÓA

Language: Spanish
References: 20
Page: 84-89
PDF size: 157.84 Kb.


ABSTRACT

Seventy years-old female with history of type 2 diabetes mellitus, hypertension and chronic kidney disease with poor adherence to drug treatment. She was treated in the nephrology department, with oral furosemide, 48 hours after she refers malaise, fever and generalized erythematous lesions, which turned into bullous lesions affecting 60% of her body surface. A diagnoses of toxic epidermal necrolysis was made. Toxic epidermal necrolysis (ten) is primarily a rare reactive dermatitis (0.4-2 cases per million), with high mortality. Therefore, it is important an early diagnosis as well as a specialized and multidisciplinary management


REFERENCES

  1. Domínguez-Borgua A, González Lucero I, Martínez Carrillo FM et al., Necrólisis epidérmica tóxica y desarrollo de abscesos hepáticos, Gac Med Mex 2015; 151: 512-8.

  2. Martínez Cabrales SA, Gómez Flores M y Ocampo Candiani J, Actualidades en farmacodermias severas: síndrome de Stevens Johnson y necrólisis epidérmica tóxica, Gac Med Mex 2015; 151: 777-87.

  3. Hoetzenecker W, Mehra T, Saulite L et al., Toxic epidermal necrolysis, F1000Research 2016; 5(F1000 Faculty Rev): 951. Doi: 10126881/f1000 research7574.1.

  4. Lyell A, Toxic epidermal necrolysis: an eruption resembling scalding of the skin, Br J Dermatol 1956; 68(11): 355-61.

  5. Chan Heng L, Stern R, Arndt K et al., The incidence of erythema multiform, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients, Arch Dermatol 1990; 126: 43-7.

  6. Mockenhaupt M, Viboud C, Dunant A et al., Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The Euroscar-study, J Invest Dermatol 2008; 128(1): 35-44.

  7. Roujeau JC, Kelly J, Naldi L et al., Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis, N Engl J Med 1995; 333: 1600-7.

  8. Roujeau JC y Stern R, Severe adverse cutaneous reactions to drugs, N Engl J Med 1994; 331(19): 1272-85.

  9. Somkrua R, Eickman E, Saokaew S et al., Association of hla-b*5801 allele and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis, bmc Medical Genetics 2011; 12: 118.

  10. Viard I, Wehrli P, Bullani R. et al., Inhibition of toxic epidermal necrolysis by blockade of cd95 with human intravenous immunoglobulin, Science 1998; 282(5388): 490-3.

  11. Viard I, Bullani R, Meda P et al., Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions, J Biol Chem 2003; 278(18): 16183-8.

  12. Ellender R, Cacey P, Albritton H et al., Clinical considerations for epidermal necrolysis, The Ochsner-Journal 2014; 14: 413-7.

  13. Saeed H, Mantagos I y Chodosh J, Complications of Stevens-Johnson syndrome beyond the eye and the skin, Burns 2016; 42(1): 20-7.

  14. Sotozono C, Ueta M, Koizumi N et al., Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications, Ophthalmology 2009; 116(4): 685-90.

  15. Chang YS, Huang FC, Tseng SH et al., Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management, Cornea 2007; 26(2): 123-9.

  16. Revuz J, Penso D, Roujeau JC et al., Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients, Arch Dermatol 1987; 123: 1160-5.

  17. Schwartz R, McDonough P y Lee B, Toxic epidermal necrolysis: Part ii . Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment, J Am Acad Dermatol 2013; 69: 187.e1-16.

  18. Hinc-Kasprzyk J, Polak-Krzeminska A y Ozóg-Zabolska I, Toxic epidermal necrolysis, Anaesthesiol Intensive Ther 2015; 47(3): 257-62.

  19. Gelfand E, Intravenous immune globulin in autoimmune and inflammatory diseases, N Engl J Med 2012; 367(21): 2015-25.

  20. Wang J, McQuilten Z y Aubron C, Intravenous immunoglobulin in critically ill adults: when and what is the evidence?, Journal of Critical Complicaciones Las complicaciones son diversas y se asemejan a las de los pacientes con quemaduras.12 Existe pérdida extensa de líquidos, lo que condiciona hipovolemia y lesión renal aguda. La pérdida de la capa protectora de la piel puede causar bacteremia y sepsis. La causa más frecuente de muerte




2020     |     www.medigraphic.com